Day One Biopharmaceuticals, Inc.
General ticker "DAWN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $837.3M (TTM average)
Day One Biopharmaceuticals, Inc. follows the US Stock Market performance with the rate: 37.8%.
Estimated limits based on current volatility of 9.8%: low 10.36$, high 12.61$
Factors to consider:
- Total employees count: 181 (+16.8%) as of 2024
- Top business risk factors: Commercial success of OJEMDA, Capital requirements, Clinical trial delays, Dependence on key products, Undesirable side effects
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.21$, 14.38$]
- 2026-12-31 to 2027-12-31 estimated range: [5.83$, 13.64$]
Financial Metrics affecting the DAWN estimates:
- Negative: with PPE of -9.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.67 <= 0.01
- Positive: Investing cash flow per share per price, % of 17.95 > -0.63
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term DAWN quotes
Long-term DAWN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $131.16MM | $158.18MM |
| Operating Expenses | $206.06MM | $348.43MM | $285.93MM |
| Operating Income | $-206.06MM | $-217.27MM | $-127.75MM |
| Non-Operating Income | $17.15MM | $128.92MM | $18.45MM |
| R&D Expense | $130.52MM | $227.70MM | $148.13MM |
| Income(Loss) | $-188.92MM | $-88.35MM | $-109.30MM |
| Taxes | $0.00MM | $7.14MM | $-1.98MM |
| Profit(Loss)* | $-377.83MM | $-183.85MM | $-107.32MM |
| Stockholders Equity | $346.54MM | $502.75MM | $441.16MM |
| Inventory | $0.00MM | $3.32MM | $6.33MM |
| Assets | $376.05MM | $582.79MM | $507.83MM |
| Operating Cash Flow | $-146.85MM | $-78.11MM | $-103.76MM |
| Capital expenditure | $3.22MM | $2.17MM | $0.32MM |
| Investing Cash Flow | $128.38MM | $-230.99MM | $174.65MM |
| Financing Cash Flow | $164.00MM | $203.29MM | $1.22MM |
| Earnings Per Share** | $-4.74 | $-1.96 | $-1.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.